Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05557279 · ClinicalTrials.gov registry record · Phase 4
Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks
A Phase 4 study of Overactive Bladder, sponsored by Loyola University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05557279 is a Phase 4 study of Overactive Bladder that is actively recruiting participants, run by Loyola University. The registered enrollment target is 40 participants, below the 211-participant average among 45 other Overactive Bladder trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05557279, a Phase 4 study of Overactive Bladder, is actively recruiting participants, sponsored by Loyola University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn about how the use of 500 mg of dried cranberry powder extract (NDS-446) changes the bacteria that normal reside in the bladder of women who don't have urinary leakage problems but do have problems with urinary urgency and frequency.
Conditions Studied
Interventions
- DRUG 500 mg NDS-446
Study Locations (1)
Illinois
- Loyola Medical Center - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05557279
The ClinicalTrials.gov registry entry for NCT05557279 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 211-participant average among 45 other Overactive Bladder trials with a reported enrollment target (81% lower). The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Overactive Bladder appearing as the primary indexed condition, and to 1 intervention - of which 500 mg NDS-446 is the first listed.
NCT05557279 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05557279 about?
NCT05557279 is a clinical study titled "Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks". The purpose of this study is to learn about how the use of 500 mg of dried cranberry powder extract (NDS-446) changes the bacteria that normal reside in the bladder of women who don't have urinary leakage problems but do have problems with urinary urgency and frequency.
What is the current status of trial NCT05557279?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2023-01-01. Estimated completion is 2025-12-01.
What conditions does trial NCT05557279 study?
This clinical trial studies the following conditions: Overactive Bladder.
What interventions are being tested in trial NCT05557279?
The interventions under investigation include: 500 mg NDS-446 (DRUG).
Who is sponsoring clinical trial NCT05557279?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05557279 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bladder Botox UTI Antibiotic Prophylaxis
RECRUITING · Phase 4
-
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
RECRUITING · Phase 4
-
TReating Incontinence for Underlying Mental and Physical Health
RECRUITING · Phase 4
-
Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
COMPLETED · Phase 4
-
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
COMPLETED · Phase 4
-
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.